Reviews/Ssris and Snris/Paroxetine and venlafaxine cause more severe discontinuation syndrome than other agents
· SS-SAF-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
This claim has two halves. For paroxetine, several controlled studies agree it causes more discontinuation symptoms than fluoxetine and sertraline [1][2][14] and more than escitalopram [15], and the severity seems to track how quickly the drug leaves the body [2]. For venlafaxine the evidence is thinner: one small study compares it only against placebo [4], and helpline call data groups it with paroxetine as the most reported [9]. The panel saw the overall direction as sound but noted the claim says 'more than other agents', and no study here compares these drugs against tricyclics or MAOIs, with the helpline data actually finding MAOIs had the highest reporting rate relative to prescriptions [9]. For those reasons the verdict sits in a middle band rather than the top one.
Controlled interruption studies show paroxetine produces more discontinuation-emergent symptoms than fluoxetine and sertraline, with fluoxetine-treated patients experiencing fewer events (p < .001) [1] and placebo substitution for paroxetine increasing the number and severity of symptoms more than for sertraline or fluoxetine [2]. A clinical investigation found discontinuation syndrome in 26 patients (26.8%), of whom 22 (84.6%) had received paroxetine versus 4 (15.4%) fluoxetine [14], and a pooled analysis found escitalopram caused significantly fewer discontinuation symptoms than paroxetine (DESS increase 1.6 vs 3.9; p < 0.01) [15]. For venlafaxine, seven (78%) of nine venlafaxine-treated versus two (22%) of nine placebo-treated patients reported adverse events after discontinuation (N=20) [4], and helpline data recorded 690 calls (39.36%) for paroxetine and 252 (14.38%) for venlafaxine [9]. Severity appears related to plasma elimination characteristics [2]. The contested point: The division is over 'more than other agents': the paroxetine comparisons are only against other SSRIs [1][2][15], no study here compares either drug against tricyclics or MAOIs, and [9] reports MAOIs had the highest rate of reactions relative to prescriptions. The venlafaxine limb also rests on a single placebo-controlled trial with no active comparator [4] plus helpline data confounded by prescribing volume and a BBC 'Panorama' programme that raised paroxetine calls ten-fold [9].
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Ssris and Snris, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The venlafaxine limb has no active comparator in the corpus: [4] compares venlafaxine only to placebo (78% vs 22%, N=20), which cannot establish 'more severe than other agents'. The claim's venlafaxine half is unsupported by any head-to-head primary trial here.
'Other agents' overreaches the evidence: the paroxetine RCTs [1][2] compared it only against fluoxetine and sertraline, and [15] only against escitalopram. [9] reports that MAOIs had the highest rate of reactions relative to prescriptions, directly contradicting a blanket 'more than other agents'.
Where it remains uncertain. No study here compares these drugs against tricyclics or MAOIs, and [9] found MAOIs had the highest reporting rate relative to prescriptions, while the venlafaxine limb rests on one placebo-only trial (N=20) [4] and media-amplified helpline reports [9].
Aleatory
The venlafaxine discontinuation result rests on nine venlafaxine-treated subjects (N=20 total) [4], so the per-patient event rate is imprecise.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
RCT head-to-head placing paroxetine above fluoxetine for discontinuation severity.
“Following interruption of therapy, fluoxetine-treated patients experienced fewer discontinuation-emergent events than either sertraline-treated or paroxetine-treated patients (p < .001).”
Panel auditInternal validity: high · scope of inference: Remitted depressed adults on maintenance SSRI undergoing abrupt 5-8 day interruption; paroxetine vs other SSRIs only.Key limitations: venlafaxine not tested · abrupt interruption not gradual taper · half-life confound drives direction
Double-blind trial showing paroxetine the most severe limb; and 'severity of symptoms vary among SSRIs in a fashion that appears to be related to plasma elimination characteristics' supplies the short-half-life mechanism linking both drugs.
“Placebo substitution for paroxetine was associated with increases in the number and severity of adverse events following the second missed dose, and increases in functional impairment at five days.”
Panel auditInternal validity: high · scope of inference: Patients on SSRI maintenance undergoing brief interruption; paroxetine vs other SSRIs, severity tied to elimination half-life.Key limitations: venlafaxine not tested · no numeric effect sizes in abstract · brief interruption not clinical taper
Only corpus evidence that venlafaxine causes discontinuation-emergent events, but versus placebo and N=20, no active comparator.
“seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine placebo-treated patients reported the emergence of adverse events, a statistically significant difference.”
Panel auditInternal validity: low · scope of inference: Major-depression outpatients stopping venlafaxine ER; venlafaxine vs placebo only, not a between-agent ranking.Key limitations: no active comparator · tiny sample · cannot support 'more than other agents'
3 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Strong comparative RCT support for paroxetine and coherent mechanism, but a genuine gap in head-to-head venlafaxine evidence and an untested generalization to all 'other agents' hold this below the Established band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Head-to-head venlafaxine versus active comparators. The venlafaxine limb rests only on placebo comparison [4] and confounded reports [9], so its claim to be 'more severe than other agents' is untested. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-blind discontinuation trial randomising venlafaxine against SSRIs and other classes with a standardised severity scale.
Open question: Is venlafaxine discontinuation more severe than that of other active antidepressants, not just placebo? Why it is still open: The only venlafaxine study here is placebo-controlled with no active comparator (N=20) [4].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19